Robert W. Baird Cuts Tandem Diabetes Care (NASDAQ:TNDM) Price Target to $37.00

Tandem Diabetes Care (NASDAQ:TNDM - Free Report) had its target price lowered by Robert W. Baird from $39.00 to $37.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a neutral rating on the medical device company's stock.

TNDM has been the topic of several other reports. The Goldman Sachs Group assumed coverage on shares of Tandem Diabetes Care in a research report on Friday, October 4th. They set a "neutral" rating and a $46.00 price target on the stock. Canaccord Genuity Group started coverage on shares of Tandem Diabetes Care in a report on Thursday, August 8th. They issued a "buy" rating and a $57.00 target price on the stock. Royal Bank of Canada began coverage on Tandem Diabetes Care in a report on Wednesday, October 2nd. They set an "outperform" rating and a $65.00 price target for the company. Piper Sandler reissued an "overweight" rating and set a $55.00 price target (up previously from $50.00) on shares of Tandem Diabetes Care in a research report on Friday, August 2nd. Finally, UBS Group raised Tandem Diabetes Care to a "hold" rating in a research report on Friday, August 2nd. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $54.13.

Tandem Diabetes Care Stock Down 2.7 %

Shares of NASDAQ:TNDM traded down $0.92 during trading on Thursday, hitting $33.32. 3,585,204 shares of the company were exchanged, compared to its average volume of 1,596,435. Tandem Diabetes Care has a fifty-two week low of $13.82 and a fifty-two week high of $53.69. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of -15.94 and a beta of 1.36. The company has a current ratio of 3.05, a quick ratio of 2.38 and a debt-to-equity ratio of 1.31. The firm has a fifty day moving average price of $38.99 and a two-hundred day moving average price of $41.82.

Institutional Trading of Tandem Diabetes Care

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Assetmark Inc. acquired a new position in shares of Tandem Diabetes Care during the 3rd quarter worth approximately $29,000. ORG Wealth Partners LLC bought a new stake in shares of Tandem Diabetes Care in the third quarter valued at approximately $30,000. ORG Partners LLC acquired a new stake in Tandem Diabetes Care during the second quarter worth approximately $31,000. Headlands Technologies LLC acquired a new stake in Tandem Diabetes Care during the first quarter worth approximately $35,000. Finally, Waldron Private Wealth LLC bought a new position in Tandem Diabetes Care during the 3rd quarter worth $50,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.